May 24, 2024
Zambia Cholera Vaccines Market

Zambia Cholera Vaccines Market Trends By Increasing Government Focus on Preventive Healthcare

Zambia cholera vaccines have gained prominence in the recent years due to increasing government focus on preventive healthcare and awareness regarding the deadly infections caused by cholera bacteria. Cholera vaccines help in building immunity against cholera and provide significant protection against the disease. They aid in preventing severe cases of cholera and even deaths. The vaccine market is driven by outbreaks in the region and efforts made to include cholera vaccines in national immunization programs.

The Global Zambia Cholera Vaccines Market is estimated to be valued at US$ 1.47 million in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031.

Cholera vaccines are oral vaccines that help the body develop immunity to cholera. They are affordable and can significantly reduce the risk of getting sick from cholera if a person is exposed to the disease-causing bacteria. Administering cholera vaccines helps limit the spread of the disease during outbreaks.

Key Takeaways

Key players operating in the Zambia cholera vaccines are Biovac Inc., Valneva SE., EMERGENT, Astellas Pharma Inc, Sanofi, EUBIOLOGICS CO., LTD,Johnson & Johnson Services Inc., Celldex Therapeutics.

The demand for Zambia Cholera Vaccines Market Growth in due to recurrent cholera outbreaks in the country over the past decades. The government is focusing on immunization programs and emergency vaccination campaigns to control the spread of the disease.

Major global vaccine manufacturers are focusing on geographical expansion and capacity enhancement in Africa. Partnerships with governments and international organizations are being forged to develop affordable cholera vaccine stocks for mass immunization programs.

Market Key Trends

One of the key trends in the Zambia cholera vaccines market is the development of affordable oral cholera vaccines with longer shelf life at ambient temperatures. This is enabling their use for pre-emptive mass immunization campaigns in high-risk regions like Zambia. Researchers are engineering vaccine strains and delivery formulations to achieve thermal stability for 3-5 years at 25°C. This increased thermostability widens the implementation window and makes stockpiling vaccines preceding outbreak seasons feasible. Partnerships between international organizations like WHO and vaccine producers are fostering trials of such vaccines for cholera control in Africa. The innovations in thermal stability will have a major positive impact on Zambia’s cholera immunization programs.

Porter’s Analysis

Threat of new entrants: Low as requires massive investments and long regulatory approvals.

Bargaining power of buyers: Moderate as buyers have a choice of substitutes like Oral Rehydration Salts.

Bargaining power of suppliers: High as supplies are concentrated with limited global players.

Threat of new substitutes: Moderate as buyers can opt for affordable substitutes like Oral Rehydration Salts.

Competitive rivalry: High as market has major global players with intense price competition.

Geographical Regions

Sub-Saharan Africa concentrated in terms of value due to high disease prevalence. Over 20 million cases reported each year making it a major market currently.

Asia Pacific is the fastest growing region for the Zambia Cholera Vaccines Market. Increasing investments by regional governments towards immunization programs and economic growth driving demand. Countries like India and China have emerged as key markets. Rising awareness and improving access is further fueling market growth in this region.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it